TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05147298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth phone program
Description: The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth phone program
Description: The automated eHealth phone program uses text to speech technology to deliver educational content to increase awareness, confidence, and motivation for physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environment program
Description: The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environment program
Description: The environment surrounding the PHDs will be changed to make it more amenable to walking by creating walking trails and walking maps and using Healthy Living Advocates (HLA)-led walking groups within the community. Also advocating for changes to the built environment.
Study: NCT01692145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05744102

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI Image
Description: MRI sequences
Study: NCT06031961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: melatonin
Description: We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
Study: NCT06385847

Intervention type: DRUG
Group type: OTHER
Intervention: Zoladex
Description: Patients received 3.6 mg subcutaneous Zoladex

Intervention type: DRUG
Group type: OTHER
Intervention: Zoladex
Description: Patients received 3.6 mg subcutaneous Zoladex

Intervention type: DRUG
Group type: OTHER
Intervention: LY01005
Description: Patients received 3.6 mg intramuscular LY01005

Intervention type: DRUG
Group type: OTHER
Intervention: LY01005
Description: Patients received 3.6 mg intramuscular LY01005
Study: NCT06469567

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient Counselling
Description: Doctor's counselling using Culturally-responsive pamphlet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Counselling
Description: Doctor's counselling using Culturally-responsive pamphlet
Study: NCT06311747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculo-motor exercises
Description: Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
Study: NCT04488861

Intervention type: OTHER
Intervention: Non-interventional cohort study
Description: Non-interventional cohort study

Intervention type: OTHER
Intervention: Non-interventional cohort study
Description: Non-interventional cohort study

Intervention type: OTHER
Intervention: Non-interventional cohort study
Description: Non-interventional cohort study
Study: NCT05557071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Behaviour Change Platform
Description: Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect.
Study: NCT04920747

Intervention type: DRUG
Intervention: Taxane
Description: docetaxel or paclitaxel
Study: NCT05455372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI quadruple therapy
Description: PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI quadruple therapy
Description: PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
Study: NCT05146206

Intervention type: OTHER
Intervention: Observational
Description: In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.

Intervention type: OTHER
Intervention: Observational
Description: In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
Study: NCT05501782

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
Study: NCT06541639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVM16
Description: cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVM16
Description: cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVM16
Description: cancer vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVM16
Description: cancer vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD1 antibody
Study: NCT05987098

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BBPA PET examination
Description: A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
Study: NCT06478134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimix tear substitutes
Description: Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid tear substitute
Description: Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
Study: NCT05585554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRIdian
Description: Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
Study: NCT05574907

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT scan
Description: Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
Study: NCT06301347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning through Play Plus
Description: Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
Study: NCT04856397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Implant in Applicator
Description: Dexamethasone intravitreal implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Implant in Applicator
Description: Dexamethasone intravitreal implant

Intervention type: DRUG
Group type: OTHER
Intervention: Eylea
Description: anti-VEGF medication
Study: NCT04759846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: A smaller dose than the dose approved for patients with normal hepatic function has been defined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib + Binimetinib
Description: A smaller dose than the dose approved for patients with normal hepatic function has been defined
Study: NCT04856397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: anti-VEGF medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: anti-VEGF medication

Intervention type: DRUG
Group type: OTHER
Intervention: Eylea
Description: anti-VEGF medication
Study: NCT04330378

Intervention type: OTHER
Intervention: Hospital-at-home
Description: As per experimental arm

Intervention type: OTHER
Intervention: Usual in-hospital care
Description: As per control arm

Intervention type: OTHER
Intervention: Usual in-hospital care
Description: As per control arm
Study: NCT06030960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Virtual Reality (VR) Stabilization Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Exercises
Description: Regular Stabilization Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Exercises
Description: Regular Stabilization Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient instructions and education
Description: a unified form of patient instructions and education in regards of LBP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient instructions and education
Description: a unified form of patient instructions and education in regards of LBP
Study: NCT05029011

Intervention type: DEVICE
Intervention: BRAEBON VTS
Description: The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
Study: NCT05648396

Intervention type: OTHER
Intervention: FFRangio
Description: Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.

Intervention type: OTHER
Intervention: FFRangio
Description: Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
Study: NCT06428864

Intervention type: DEVICE
Intervention: Plaster cast
Description: Wearing a Garchois brace produced after a plaster cast

Intervention type: DEVICE
Intervention: 3D Scanning
Description: Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
Study: NCT06475794

Intervention type: OTHER
Intervention: Patients with osteoporosis group
Description: Pain, Q angle, muscle strength and foot posture will be evaluated.

Intervention type: OTHER
Intervention: Patients with osteoarthritis group
Description: Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
Study: NCT06059729

Intervention type: DEVICE
Group type: OTHER
Intervention: Al-Lisaan
Description: Al-Lisaan is a digital application for the self assessment and management of adult stutters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Al-Lisaan
Description: Al-Lisaan is a digital application for the self assessment and management of adult stutters.
Study: NCT05739305

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
Study: NCT05190471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Description: Dose escalation of BP1002 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Description: Dose escalation of BP1002 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (in combination with BP1002)
Description: Dose expansion of BP1002 in combination with decitabine
Study: NCT05054465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
Study: NCT05041725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Injection [Byfavo]
Description: Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
Study: NCT05840900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mindfulness Training
Description: Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
Study: NCT05225636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Extraction of intracranial thrombus in an acute large vessel occlusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Extraction of intracranial thrombus in an acute large vessel occlusion
Study: NCT05130346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
Study: NCT05086419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-symptom threshold aerobic exercise
Description: For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
Study: NCT04864717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100mg po once daily x 6 months
Description: active intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin 40 mg po once daily x 6 months
Description: active intervention
Study: NCT05739305

Intervention type: OTHER
Intervention: Risk factor
Description: No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
Study: NCT05268016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME3183
Description: ME3183 capsule
Study: NCT06215417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Arthroscopic rotator cuff repair augmented with graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Arthroscopic rotator cuff repair augmented with graft.
Study: NCT05969405

Intervention type: PROCEDURE
Intervention: Laparoscopic staging
Description: Laparoscopic staging

Intervention type: PROCEDURE
Intervention: Robotic staging
Description: Robotic staging

Intervention type: PROCEDURE
Intervention: Laparotomic staging
Description: Laparotomic staging
Study: NCT06226662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Study: NCT05268016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME3183
Description: ME3183 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME3183
Description: ME3183 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME3183
Description: ME3183 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT05090605

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS

Intervention type: GENETIC
Intervention: DNA analysis
Description: GWAS
Study: NCT05976035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Structured exercise program under the supervision of a physiotherapist 3 days per week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplement
Description: Receiving supplement that are prescribed by a orthopedist every day for 8 weeks
Study: NCT05835427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Extensor Stretch
Description: Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Extensor Stretch
Description: Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
Study: NCT06217744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Intervention
Description: Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Intervention
Description: Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
Study: NCT06521112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.
Description: Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
Study: NCT06073756

Intervention type: RADIATION
Intervention: Echocardiogram
Description: Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM

Intervention type: RADIATION
Intervention: Echocardiogram
Description: Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
Study: NCT05476640

Intervention type: GENETIC
Intervention: NGS
Description: In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
Study: NCT06133478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 1
Description: 6 participants will be assigned to receive active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 2
Description: 6 participants will be assigned to receive active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 3
Description: 6 participants will be assigned to receive active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV001 active cohort 4
Description: 6 participants will be assigned to receive active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 1
Description: 2 participants will be assigned to receive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 2
Description: 2 participants will be assigned to receive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 3
Description: 2 participants will be assigned to receive placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NUV001 placebo cohort 4
Description: 2 participants will be assigned to receive placebo